quinazolines has been researched along with Kahler Disease in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, B; Mao, X; Qiao, C; Wang, Q; Wang, X; Xu, X; Xu, Y; Zeng, K; Zeng, Y; Zhang, J; Zhang, Z | 1 |
| Abibi, A; Al-Awar, R; Aman, A; Chung, KC; Griffin, C; Grouleff, J; Isaac, MB; Joseph, B; Kiyota, T; Konda, JD; Ler, S; Leung-Hagesteijn, C; Marcellus, R; Poda, G; Prakesch, MA; Strathdee, CA; Subramaniam, R; Tiedemann, RE; Uehling, DE; Zhang, AX | 1 |
| Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Du, J; Hou, J; Jiang, H; Yan, WQ | 1 |
| Cotreau, MM; Han, M; Hofmeister, CC; Isaacs, R; Jac, J; Papadopoulos, KP; Patnaik, A; Payumo, FC; Ramanathan, RK; Tibes, R; Tolcher, A; Weiss, GJ | 1 |
| Dotterweich, J; Einsele, H; Nekova, TS; Schütze, N; Stuhler, G | 1 |
| Du, J; He, J; Hou, J; Li, R; Yan, W | 1 |
| Chang, H; Chen, G; Chen, Y; Ding, J; Huang, R; Ji, D; Song, B; Yuan, L | 1 |
| Baron, F; Beguin, Y; Binsfeld, M; Caers, J; Carmeliet, G; Cohen-Solal, M; Dubois, S; Heusschen, R; Léonard, A; Mahli, N; Marty, C; Menu, E; Moermans, K; Muller, J; Plougonven, E | 1 |
| Ahn, KS; Bae, EK; Kim, BK; Kim, BS; Lee, YY; Park, J; Yoon, SS | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Goldman, B | 1 |
| He, XY; Huang, JA; Jiang, LY; Wang, YD; Xie, W | 1 |
| Baudard, M; Cremer, FW; De Vos, J; Fiol, G; Goldschmidt, H; Grau, V; Hose, D; Jourdan, E; Jourdan, M; Klein, B; Mahtouk, K; Moos, M; Moreaux, J; Raab, M; Rème, T; Rossi, JF | 1 |
| Aneja, R; Dong, JT; Gao, J; Giannis, A; Joshi, HC; Liu, C; Liu, M; Sarli, V; Sun, L; Wang, H; Zhou, J | 1 |
| Dong, RP; Eisenhauer, E; Kovacs, MJ; Marcellus, D; Mathews, S; Meyer, RM; Reece, DE | 1 |
| Belch, AR; Checkland, T; Evans, RP; Keats, JJ; Lai, R; Maxwell, CA; Naber, C; Pilarski, LM; Reiman, T; Steffler, T | 1 |
2 trial(s) available for quinazolines and Kahler Disease
| Article | Year |
|---|---|
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145.
Topics: Administration, Oral; ErbB Receptors; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2006 |
15 other study(ies) available for quinazolines and Kahler Disease
| Article | Year |
|---|---|
Novel conjugates of endoperoxide and 4-anilinoquinazoline induce myeloma cell apoptosis by inhibiting the IGF1-R/AKT/mTOR signaling pathway.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Artemisinins; Cell Line, Tumor; Gefitinib; Humans; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; G-Protein-Coupled Receptor Kinases; Humans; Mice; Models, Molecular; Molecular Structure; Multiple Myeloma; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2021 |
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Oligopeptides; Phosphoinositide-3 Kinase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Stromal Cells | 2019 |
[Effect of nuclear receptor inhibitor importazole on the proliferation and apoptosis of multiple myeloma cells].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; NF-kappa B; Quinazolines; Signal Transduction | 2013 |
Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment.
Topics: Allyl Compounds; Antineoplastic Agents; Apoptosis; Bone Marrow; Drug Screening Assays, Antitumor; Glycogen Synthase Kinase 3; Humans; Multiple Myeloma; Quinazolines; Tumor Cells, Cultured; Tumor Microenvironment | 2014 |
Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
Topics: Active Transport, Cell Nucleus; Apoptosis; beta Karyopherins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Humans; Multiple Myeloma; NF-kappa B; Quinazolines; RNA, Small Interfering; Signal Transduction; Transcription Factor RelA | 2015 |
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
Topics: 6-Aminonicotinamide; Afatinib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Glucose; Humans; Metabolome; Multiple Myeloma; Oxygen; Pentose Phosphate Pathway; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; ras Proteins; Receptor, ErbB-2; RNA, Small Interfering; TOR Serine-Threonine Kinases | 2015 |
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Topics: Administration, Oral; Animals; Benzodioxoles; Bone and Bones; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogenes; Quinazolines; src-Family Kinases | 2016 |
Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Genes, Reporter; Humans; Interleukin-6; Interleukin-7; Luciferases; Multiple Myeloma; NF-kappa B; Phosphorylation; Pyrazines; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2008 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |
[Role of PD153035 in the induction of apoptosis of XG-1 myeloma cell line].
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Humans; Multiple Myeloma; Quinazolines; STAT3 Transcription Factor; Trans-Activators | 2004 |
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.
Topics: Amphiregulin; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Proliferation; EGF Family of Proteins; ErbB Receptors; Gefitinib; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Plasma Cells; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells.
Topics: Apoptosis; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Growth Inhibitors; HSP70 Heat-Shock Proteins; Humans; Kinesins; Morpholines; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Spindle Apparatus; Transcription, Genetic; Up-Regulation | 2006 |
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Cell Line, Tumor; Flow Cytometry; Humans; Immunophenotyping; Mice; Mice, SCID; Multiple Myeloma; Organophosphates; Plasma Cells; Protein Serine-Threonine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Syndecan-1; Xenograft Model Antitumor Assays | 2008 |